- Home
- CEE vs SGMO Comparison
CEE vs SGMO Comparison
Compare CEE & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEE
- SGMO
- Stock Information
- Founded
- CEE 1990
- SGMO 1995
- Country
- CEE Germany
- SGMO United States
- Employees
- CEE N/A
- SGMO N/A
- Industry
- CEE Finance Companies
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CEE Finance
- SGMO Health Care
- Exchange
- CEE Nasdaq
- SGMO Nasdaq
- Market Cap
- CEE 105.5M
- SGMO 122.8M
- IPO Year
- CEE N/A
- SGMO 2000
- Fundamental
- Price
- CEE $16.19
- SGMO $0.50
- Analyst Decision
- CEE
- SGMO Strong Buy
- Analyst Count
- CEE 0
- SGMO 7
- Target Price
- CEE N/A
- SGMO $5.29
- AVG Volume (30 Days)
- CEE 22.0K
- SGMO 4.5M
- Earning Date
- CEE 01-01-0001
- SGMO 11-11-2025
- Dividend Yield
- CEE 3.86%
- SGMO N/A
- EPS Growth
- CEE N/A
- SGMO N/A
- EPS
- CEE N/A
- SGMO N/A
- Revenue
- CEE N/A
- SGMO $81,706,000.00
- Revenue This Year
- CEE N/A
- SGMO $21.24
- Revenue Next Year
- CEE N/A
- SGMO N/A
- P/E Ratio
- CEE N/A
- SGMO N/A
- Revenue Growth
- CEE N/A
- SGMO 565.52
- 52 Week Low
- CEE $7.80
- SGMO $0.41
- 52 Week High
- CEE $10.32
- SGMO $3.18
- Technical
- Relative Strength Index (RSI)
- CEE 47.59
- SGMO 43.36
- Support Level
- CEE $15.87
- SGMO $0.51
- Resistance Level
- CEE $16.45
- SGMO $0.56
- Average True Range (ATR)
- CEE 0.56
- SGMO 0.03
- MACD
- CEE -0.08
- SGMO -0.00
- Stochastic Oscillator
- CEE 41.32
- SGMO 29.08
About CEE The Central and Eastern Europe Fund Inc. (The)
CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.